Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 29:8:521.
doi: 10.3389/fneur.2017.00521. eCollection 2017.

Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement

Nakul Katyal  1 , Raghav Govindarajan  1
Affiliations
Review

Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement

Nakul Katyal et al. Front Neurol. .

Abstract

Amyotrophic lateral sclerosis (ALS) is a clinically progressive neurodegenerative syndrome predominantly affecting motor neurons and their associated tracts. Riluzole and edaravone are the only FDA certified drugs for treating ALS. Over the past two decades, almost all clinical trials aiming to develop a successful therapeutic strategy for this disease have failed. Genetic complexity, inadequate animal models, poor clinical trial design, lack of sensitive biomarkers, and diagnostic delays are some of the potential reasons limiting any significant development in ALS clinical trials. In this review, we have outlined the possible reasons for failure of ALS clinical trials, addressed the factors limiting timely diagnosis, and suggested possible solutions for future considerations for each of the shortcomings.

Keywords: amyotrophic lateral sclerosis; animal models; biomarkers; clinical trials; genetic complexity; infrastructural issues.

PubMed Disclaimer

References

    1. Amyotrophic Lateral Sclerosis (ALS) Fact Sheet. NINDS, NIH; Publication No. 16–91 (2013).
    1. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (2002) 2:CD001447.10.1002/14651858.CD001447.pub3 - DOI - PubMed
    1. Mehta P, Kaye W, Bryan L, Larson T, Copeland T, Wu J, et al. Prevalence of amyotrophic lateral sclerosis – United States, 2012–2013. MMWR Surveill Summ (2016) 65:1–12.10.15585/mmwr.ss6508a1 - DOI - PubMed
    1. Su XW, Xiaowei W, Broach JR, Connor JR, Gerhard GS, Simmons Z. Genetic heterogeneity of ALS: implications for clinical practice and research: ALS Genetics. Muscle Nerve (2014) 49:786–803.10.1002/mus.24198 - DOI - PubMed
    1. Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 11:323–30.10.1016/S1474-4422(12)70043-1 - DOI - PMC - PubMed

LinkOut - more resources